OSR2 and neoplasm: In solid tumor models, the absence of Osr2 can alleviate the exhausted state of transferred tumor-specific T cells and enhance their control of tumors, suggesting that Osr2, as a biomechanical checkpoint, holds promise as a new target for solid tumor immunotherapy.